NOVEL BIFIDOBACTERIUM BREVE IDCC 4401 STRAIN AND ITS DEAD CELL ID-BBR4401 HAVING EXCELLENT ACID TOLERANCE AND BILE TOLERANCE AND PROPHYLACTIC OR THERAPEUTIC EFFECT ON DYSLIPIDEMIA
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Sep 14, 2023
app pub date -
Dec 30, 2022
filing date -
Jun 30, 2020
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention relates to a novel Bifidobacterium breve IDCC 4401 strain (accession number: KCTC13169BP) and dead cell thereof ID-BBR4401, which are superb in acid tolerance and bile tolerance and have a preventive or therapeutic effect on dyslipidemia. Having not only an excellent effect of reducing a cholesterol level in the body but alto a very high level of acid tolerance and bile tolerance in contrast to previously known B. breve, the novel Bifidobacterium breve MCC 4401 strain (accession number: KCTC13169BP) of the present invention well exhibits the functionality that the strain has in the digestive duct of animals (especially humans), has an excellent growth potential, and provides sustainable and effective functionality of reducing a level of cholesterol in vivo.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully